Aurobindo Pharma Ltd
₹1705
+10.50 (0.62%)
Fri, 06 Nov 2026, 09:38 pm
Health Technology
Pharmaceuticals: Other
24.5KAurobindo Pharma Share Price Live Chart
1 Day
+10.50 (0.62%)
No Result Found
Summary
Market Cap (in Cr)
97877.53
Net Profit (in Cr)
3502.97
P/B
2
Sector P/E
38.06
P/E
21.60
EV/EBITDA
10.16
Debt/Equity (Industry)
0.19
Interest Cover (Industry)
13.14
ROCE (Industry)
12.29
RONW (Industry)
10.69
ROE
9.93
ROCE
12.43
Debt/Equity
0.23
EPS (TTM)
65.71
Dividend Yield
0.24
Book Value
658.53
Interest Cover
14.31
Analysis
all
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (11.4x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
- Aurobindo Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Aurobindo Pharma's earnings are expected to exceed the low risk growth rate next year.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Aurobindo Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Aurobindo Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
- Cash flow for Aurobindo Pharma is expected to decrease over the next 2 years.
- Aurobindo Pharma's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).
Shareholding
| Shareholders | SEPT 2026 | JUN 2026 | MAR 2026 | DEC 2025 | SEPT 2025 |
|---|---|---|---|---|---|
| Promoters | 51.88 | 51.88 | 51.82 | 51.82 | 51.82 |
| FII | 17.41 | 16.38 | 15.24 | 13.94 | 14.21 |
| DII | 24.42 | 25.10 | 25.87 | 27.68 | 27.60 |
| Public | 6.29 | 6.64 | 7.08 | 6.55 | 6.38 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1982.63 | 1815.33 | 1748.37 | 1648.03 | 1581.07 | 1480.73 | 1313.43 |
| Fibonacci | 1815.33 | 1751.42 | 1711.94 | 1648.03 | 1584.12 | 1544.64 | 1480.73 |
| Camarilla | 1727.41 | 1712.07 | 1696.74 | 1648.03 | 1666.06 | 1650.73 | 1635.39 |
Pivots Level: Classic
R3
+334.60
1982.63
R2
+167.30
1815.33
R1
+100.33
1748.37
S1
-66.97
1581.07
S2
-167.30
1480.73
S3
-334.60
1313.43
Moving Average
Period
Value
10-EMA
1708.51
20-EMA
1684.94
30-EMA
1676.73
50-EMA
1662.11
100-EMA
1610.11
200-EMA
1507.25
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 04 Nov 2026 | board-meetings | Quarterly Results, Interim Dividend | |
| 04 Nov 2026 | dividend | ₹7.00 Dividend /Share | 11 Nov 2026 |
| 29 Jul 2026 | agm | ||
| 21 May 2026 | board-meetings | Accounts | |
| 06 Apr 2026 | buyback | ||
| 09 Feb 2026 | board-meetings | Quarterly Results, Nine Months Results | |
| 05 Nov 2025 | board-meetings | Quarterly Results | |
| 12 Aug 2025 | agm | ||
| 04 Aug 2025 | dividend | ₹4.00 Dividend /Share | 08 Aug 2025 |
| 08 Jul 2025 | dividend | Interim Dividend - Rs. - 4 | 08 Aug 2025 |
Peer Comparison
Aurobindo Pharma Ltd
Laurus Labs Ltd
Divis Laboratories Ltd
Zydus Lifesciences Ltd
Sun Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Aurobindo Pharma Ltd About
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln
Founded
1986
Headquarters
CEO
M R Kumar
Employees
Contact
Website
http://www.aurobindo.com
cs@aurobindo.com; investorgrievances@aurobindo.com
Phone
91-40-23736370
Location
Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038
Aurobindo Pharma Ltd Company History
| Year | History |
|---|---|
| 2020 |
|
| 2021 |
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| GOLDMAN SACHS BANK EUROPESE - ODI | block | Buy | 106228 | 1107 | 16 Oct 2025 |
| GOLDMAN SACHS (SINGAPORE) PTE.- ODI | block | Sell | 106228 | 1107 | 16 Oct 2025 |
| MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND | block | Buy | 27571 | 1160.1 | 25 Jan 2024 |
| MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUND | block | Buy | 15950 | 1160.1 | 25 Jan 2024 |
| BNP PARIBAS ARBITRAGE | block | Sell | 150001 | 1160.1 | 25 Jan 2024 |
| MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUND | block | Buy | 862 | 1160.1 | 25 Jan 2024 |
| MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND | block | Buy | 106480 | 1160.1 | 25 Jan 2024 |
| SOCIETE GENERALE | block | Buy | 1484323 | 1160.1 | 25 Jan 2024 |
| BNP PARIBAS ARBITRAGE | block | Sell | 1484323 | 1160.1 | 25 Jan 2024 |
| MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND | block | Buy | 53641 | 1160.1 | 25 Jan 2024 |
Frequently Asked Questions
1.What is the stock price of Aurobindo Pharma Ltd?
As of 07/11/2026 at 3:08 AM, Aurobindo Pharma Ltd shares are trading at ₹1705.
2.What is the market cap. of Aurobindo Pharma Ltd?
As of 07/11/2026, the market capitalization of Aurobindo Pharma Ltd is ₹97,756.70 crore.
3.When was Aurobindo Pharma Ltd founded?
Aurobindo Pharma Ltd was founded in 1986.
4.What are the P/E and P/B ratios of Aurobindo Pharma Ltd?
As of 07/11/2026, Aurobindo Pharma Ltd has a P/E ratio of 26.64 and a P/B ratio of 2.00.
5.How can I buy shares of Aurobindo Pharma Ltd?
You can buy shares of Aurobindo Pharma Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.
6.What is the shareholding pattern of Aurobindo Pharma Ltd?
As of September,2026, promoters hold 51.88% in Aurobindo Pharma Ltd, while FIIs, DIIs and public shareholders hold 17.41%, 24.42% and 6.29%, respectively.
7.Does Aurobindo Pharma Ltd pay dividends?
Yes, Aurobindo Pharma Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹7.00 Dividend /Share per share.
8.What is the dividend yield of Aurobindo Pharma Ltd?
As of 07 November, 2026, the dividend yield of Aurobindo Pharma Ltd stands at 0.24%.
9.What are the latest financial results of Aurobindo Pharma Ltd?
For the financial year ended March 2025, Aurobindo Pharma Ltd reported revenue of ₹31,403.00 crore and a net profit of ₹3,486.00 crore.
10.What is the Stock symbol of Aurobindo Pharma Ltd?
AUROPHARMA is the stock symbol of Aurobindo Pharma Ltd.
11.Who is the CEO of Aurobindo Pharma Ltd?
The CEO of Aurobindo Pharma Ltd is M R Kumar.
